Mark Cobbold

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

Journal: Journal for immunotherapy of cancer

Published: July 07, 2025

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2025

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

Journal: Nature

Published: February 12, 2025

The differential immunological impact of photon vs proton radiation therapy in high-grade lymphopenia in patients with gastrointestinal tumors.

The differential immunological impact of photon vs proton radiation therapy in high-grade lymphopenia in patients with gastrointestinal tumors.

Journal: Clinical and experimental immunology

Published: July 18, 2024

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 12, 2024

Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Journal: Cancer research

Published: May 02, 2024

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Journal: Nature communications

Published: July 10, 2023

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

Journal: The Journal of clinical investigation

Published: March 09, 2023

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information.

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information.

Journal: Nucleic acids research

Published: December 20, 2021

Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Journal: Cancer research

Published: July 09, 2021

Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer.

Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer.

Journal: Frontiers in immunology

Published: June 10, 2021

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 17, 2021

Showing 1-12 of 45

Last Updated: 09/26/2026